Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to $2.0 million.

  • Mimedx Group's Change in Accured Expenses fell 39.95% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 250.32%. This contributed to the annual value of $2.9 million for FY2024, which is 58.34% up from last year.
  • Per Mimedx Group's latest filing, its Change in Accured Expenses stood at $2.0 million for Q3 2025, which was down 73.12% from $7.6 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx Group's Change in Accured Expenses peaked at $8.0 million during Q3 2022, and registered a low of -$11.4 million during Q2 2021.
  • Its 3-year average for Change in Accured Expenses is $936,000, with a median of $1.9 million in 2023.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 256.94% in 2021, then skyrocketed by 2,925.65% in 2025.
  • Over the past 5 years, Mimedx Group's Change in Accured Expenses (Quarterly) stood at -$3.7 million in 2021, then skyrocketed by 117.57% to $655,000 in 2022, then soared by 525.50% to $4.1 million in 2023, then increased by 2.59% to $4.2 million in 2024, then slumped by 39.95% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $7.6 million for Q2 2025, and -$4.1 million during Q1 2025.